Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrosis and related diseases. The company develops integrin-based therapeutics, with product candidates targeting fibrotic conditions. Pliant has pursued orphan drug and Fast Track designations for its pipeline and has engaged in research collaborations and license agreements to advance its drug development programs.
Q2 FY2026 — expected 2026-08-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-11 | 2025-12-31 | 0001746473-26-000037 | EDGAR | 79K words |
| 2025-03-03 | 2024-12-31 | 0001746473-25-000054 | EDGAR | 82K words |
| 2024-02-27 | 2023-12-31 | 0001746473-24-000043 | EDGAR | 80K words |
| 2023-03-09 | 2022-12-31 | 0001746473-23-000008 | EDGAR | 84K words |
| 2022-03-01 | 2021-12-31 | 0001746473-22-000010 | EDGAR | — |
| 2021-03-16 | 2020-12-31 | 0001564590-21-013589 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-11 | 2026-06-30 | 0001746473-26-000113 | EDGAR | 52K words |
| 2025-11-06 | 2025-09-30 | 0001746473-25-000175 | EDGAR | 54K words |
| 2025-08-07 | 2025-06-30 | 0001746473-25-000150 | EDGAR | 54K words |
| 2025-05-08 | 2025-03-31 | 0001746473-25-000099 | EDGAR | 53K words |
| 2024-11-07 | 2024-09-30 | 0001746473-24-000171 | EDGAR | 54K words |
| 2024-08-07 | 2024-06-30 | 0001746473-24-000145 | EDGAR | 54K words |
| 2024-05-06 | 2024-03-31 | 0001746473-24-000076 | EDGAR | 53K words |
| 2023-11-09 | 2023-09-30 | 0001746473-23-000074 | EDGAR | 58K words |
| 2023-08-09 | 2023-06-30 | 0001746473-23-000053 | EDGAR | 56K words |
| 2023-05-09 | 2023-03-31 | 0001746473-23-000031 | EDGAR | 56K words |
| 2022-11-08 | 2022-09-30 | 0001746473-22-000031 | EDGAR | 60K words |
| 2022-08-08 | 2022-06-30 | 0001746473-22-000027 | EDGAR | 58K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-11 | 0001746473-26-000115 | EDGAR | 2K words |
| 2026-07-13 | 0001746473-26-000107 | EDGAR | 1K words |
| 2026-03-30 | 0001746473-26-000046 | EDGAR | 1K words |
| 2026-03-11 | 0001746473-26-000039 | EDGAR | 2K words |
| 2026-03-03 | 0001746473-26-000024 | EDGAR | 1K words |
| 2025-12-16 | 0001746473-25-000182 | EDGAR | 1K words |
| 2025-12-08 | 0001746473-25-000179 | EDGAR | 1K words |
| 2025-11-06 | 0001746473-25-000173 | EDGAR | 2K words |
| 2025-10-24 | 0001746473-25-000159 | EDGAR | 1K words |
| 2025-10-20 | 0001193125-25-243619 | EDGAR | 1K words |
103 total filings indexed. 75 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001746473 |
| Ticker | PLRX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.pliantrx.com |
| Listed | 2020-06-03 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/PLRX (~200 tokens, structured JSON with cryptographic provenance)